Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14700307 | 1.00 | HRH3 (0.35) | HRH3L3MBTL1PDE10ASLC6A2SLC6A4 | |
| SCHEMBL733358 | 1.00 | HRH3 (0.35) | HRH3L3MBTL1PDE10ASLC6A2SLC6A4 | |
| SCHEMBL733502 | 0.89 | HRH3 (0.35) | HRH3L3MBTL1PDE10ASLC6A4GRM4 | |
| SCHEMBL3262449 | 0.89 | HRH3 (0.35) | HRH3L3MBTL1PDE10ASLC6A4GRM4 | |
| SCHEMBL15039688 | 0.88 | HRH3 (0.35) | HRH3PDE10ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2307110 | 0.85 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL731967 | 0.82 | KMT2A (0.51) | GRM4 | |
| SCHEMBL733745 | 0.82 | HRH3 (0.35) | HRH3GRM4 | |
| SCHEMBL1947120 | 0.81 | RXFP1 (0.40) | — | |
| SCHEMBL1945984 | 0.80 | MDM2 (0.34) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | ANDREWS MARK DAVID | 2011-06-09 | — | — | US | disclosed |
| EP-2326638-A1 | DIAZEPINE AND DIAZOCANE COMPOUNDS AS MC4 AGONISTS | Pfizer Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136814-A1 | Diazepine and Diazocane Compounds As MC4 Agonists | MC4R, CHRM4, GPR4 | HRH3 37/4885L3MBTL1 2132/4885PDE10A 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.